We observed that liraglutide reversed the 2.6-fold increase in Fis1 levels in brains from female mice with early AD-like pathology (F(2,15) = 5.358, p = 0.018; Figure 7A), while the 1.8-fold lower OPA1 levels were only partially reversed upon liraglutide administration (by 1.6-fold) in female mice with early AD-like pathology (F(2,15) = 3.636, p = 0.052; Figure 7B). This evidence concerns the gene FIS1 and Alzheimer disease.